Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS)

Meet the patient

A 66-year-old diabetic man wakes at 4 am with central chest pressure for the last forty minutes, sweating and nauseous, unrelieved by two puffs of his wife's glyceryl trinitrate spray. The ECG shows 1 mm of horizontal ST depression in V4 to V6 with T-wave inversion; his first high-sensitivity troponin is already twice the 99th centile.[1]

The single decision that defines his next twelve hours is the one that defines every NSTE-ACS admission: when — if at all — do I take him to the catheter laboratory? Unlike the STEMI two beds down, the right answer is not "now, everyone". It is a graded, score-driven escalation, and the GRACE score, the troponin trajectory, and the bedside phenotype together set the clock.[1]

One syndrome, one trigger — but the artery is only partly shut

NSTE-ACS is not a separate disease from STEMI; it is the same plaque rupture read through a different ECG. Every episode begins the same way: an atherosclerotic cap ruptures or erodes, exposing thrombogenic core to flowing blood, and a platelet-and-fibrin clot forms. In STEMI the clot chokes the lumen completely and the wall dies transmurally; in NSTE-ACS the clot is partial, mural, or intermittent, so enough flow survives to spare the full thickness — and the ECG shows no persistent ST elevation.[1]

That mechanistic difference is the entire teaching point. The three faces of ACS, split on the ECG and the troponin:[1]

[1]

The discriminator in one line each: STEMI is a plumbing emergency (open the artery now); NSTEMI is a risk-stratification problem (time the angiography from a score); unstable angina is NSTEMI's troponin-negative shadow, dwindling as high-sensitivity assays reclassify yesterday's "negative" troponins as small rises.[1]

Read the ECG within ten minutes — and chase the troponin

The 12-lead ECG, obtained and interpreted within 10 minutes of first medical contact, is the single most time-critical test — its first job is to exclude STEMI and its equivalents before you commit to the NSTE-ACS pathway. In NSTE-ACS itself, look for the partial-occlusion signatures:[1]

• ST depression — horizontal or downsloping, at least 0.5 mm in two contiguous leads; the commonest NSTE-ACS change.
• Deep symmetrical T-wave inversion — classically across V1 to V4 in proximal LAD disease (Wellens territory).
• Transient ST elevation that resolves — a dynamic, waxing-and-waning clot.
• Pseudo-normalisation — previously inverted T waves stand upright during pain.
• Posterior MI pattern — ST depression in V1 to V3 with tall R waves and upright T waves; record posterior leads V7 to V9.[1]

The classic trap: ST depression with tall R waves in V1 to V3 is not "ischaemic NSTEMI" — it is a true posterior STEMI-equivalent. Record V7 to V9 and activate reperfusion; do not file the patient as low-risk NSTE-ACS. Up to 20 per cent of NSTEMI patients have a normal ECG, so a clean tracing never excludes ACS — repeat every 15 to 30 minutes while pain persists.[1]

Two high-yield named ECG patterns to reproduce in a viva:[1]

• De Winter T waves — upsloping ST depression with tall symmetrical T waves in the anterior leads and no ST elevation; an LAD-occlusion equivalent masquerading as NSTE-ACS.
• Wellens syndrome — deeply inverted or biphasic T waves in V2 to V3 in a pain-free interval, signalling critical proximal LAD stenosis; a pending-anterior-MI warning.[1]

High-sensitivity cardiac troponin is the biomarker of choice — never use CK-MB or myoglobin as the primary biomarker. Sample at presentation (0-hour) and run a validated accelerated algorithm: the ESC 0-hour/1-hour pathway (three bands — rule-out, observe, rule-in — based on the absolute level and the 1-hour delta), or the 0-hour/3-hour pathway if a 1-hour assay is unavailable. Acute MI is a rise and/or fall of troponin with at least one value above the 99th centile of a healthy reference population, in the clinical context of ischaemia.[3]

Interpret the number in context, always. Troponin is chronically raised in renal failure, severe heart failure, sepsis, and pulmonary embolism — there it is injury, not infarction, and a flat (non-rising) pattern means chronic, not acute. The rise/fall, not the absolute value, is decisive.[1]

Type 1 versus Type 2 MI — the trap that wastes a cath-lab call

The Fourth Universal Definition sorts MI into five types, and the Type 1-versus-Type 2 split is the single most tested discriminator in NSTE-ACS. Most NSTE-ACS events are Type 1 — spontaneous atherothrombotic plaque disruption with intraluminal thrombus, the plaque-rupture pathway that earns the full DAPT-and-angiogram ladder. Type 2 is the trap: an oxygen supply-demand mismatch without plaque disruption, where troponin rises because demand outran supply.[1]

[1]

The classic trap: a septic, tachycardic patient with known coronary disease and a troponin bump is the ward's commonest Type 2 MI. Reaching for loading DAPT and rushing to angiography is the recurring trainee error — the artery did not rupture, the demand outran the supply, and the fix is the precipitant. This single distinction is worth a viva mark every time.[1]

How common — and why NSTE-ACS kills more patients long-term than STEMI

NSTE-ACS is the commonest form of ACS in contemporary Western registries, accounting for roughly 70 per cent of all ACS admissions. STEMI has fallen as smoking declined and prevention improved; NSTE-ACS has not, driven by an ageing, multi-morbid population. Incidence rises steeply with age and is higher in men until the menopause narrows the gap. South Asians — directly relevant to the NEET-PG and INICET population — have among the highest rates of premature coronary disease worldwide, with NSTE-ACS often presenting a decade earlier than in Europeans.[1]

Here is the counter-intuitive fact examiners love: although in-hospital mortality of NSTEMI is lower than STEMI, the 1-year and 5-year mortality of NSTE-ACS equals or exceeds that of STEMI, because NSTE-ACS patients are older, carry more comorbidity (diabetes, chronic kidney disease, prior MI), and more often have multivessel and recurrent disease. This is why the topic carries "high" weight in every exam.[1]

The risk factors for the underlying atherosclerosis are the conventional modifiable Framingham/INTERHEART cluster: tobacco smoking (the single largest population-attributable risk, especially in young South-Asian men), diabetes mellitus (doubles risk and worsens prognosis after NSTE-ACS), hypertension, dyslipidaemia (raised LDL, low HDL, raised apolipoprotein B), family history of premature coronary disease (first-degree male under 55, female under 65), age, male sex or post-menopausal, obesity and inactivity, psychosocial stress, and diet. The INTERHEART nine modifiable risk factors account for over 90 per cent of the population-attributable risk of MI.[1]

Precipitants of an acute event on a background of established (often subclinical) plaque — examiners love these: non-cardiac surgery (post-operative NSTE-ACS, the commonest peri-operative cardiac emergency), severe infection or sepsis, acute blood loss or anaemia, tachyarrhythmia (atrial fibrillation with rapid ventricular response), hypoxia (pneumonia, COPD exacerbation), cocaine or amphetamine use (spasm plus thrombosis), thyrotoxicosis, and withdrawal of antiplatelet or statin therapy (a statin holiday or stopping aspirin precipitates rebound thrombosis). Spotting a Type 2 component layered on a Type 1 event is part of the assessment.[1]

The five vicious Ps — how a partial clot causes rest ischaemia

The unifying event is myocardial ischaemia from an atherosclerotic plaque that has become unstable, and the "five vicious Ps" frame the mechanism: plaque, platelets, pressure (vasoconstriction), pumping (demand), and passage of emboli.[1]

1. Plaque disruption — two mechanisms:[1]

• Plaque rupture — a thin fibrous cap (under 65 micrometres, loaded with macrophage foam cells, scarce smooth muscle) tears, exposing the highly thrombogenic lipid/necrotic core (tissue factor, collagen, von Willebrand factor). Dominant in men and in STEMI.
• Plaque erosion — an intact but denuded endothelial surface over a proteoglycan-rich plaque recruits platelets directly, without a tear and without an exposed lipid core. Commoner in women and in sudden death, and tends to produce NSTE-ACS rather than STEMI.[1]

Everyone forgets: the plaques that rupture are typically only mildly to moderately stenotic (under 70 per cent) on prior angiography — they are vulnerable by virtue of a large lipid core, thin cap, and active inflammation, not by their luminal narrowing. A "normal" stress test or mild stenosis on a prior angiogram does not exclude future ACS.[1]

2. Platelets adhere to exposed collagen and von Willebrand factor through GP-Ib-IX-V, activate, release ADP, thromboxane A2, and serotonin, and cross-link through GP-IIb/IIIa binding fibrinogen. This is why the antiplatelet armamentarium targets three nodes: cyclo-oxygenase-1 (aspirin — blocks thromboxane A2), the P2Y12 ADP receptor (clopidogrel, prasugrel, ticagrelor), and GP-IIb/IIIa (abciximab, eptifibatide, tirofiban — the final common pathway).[5][6]

3. The coagulation cascade — tissue factor from the plaque core fires the extrinsic pathway, generating thrombin (Factor IIa), which both converts fibrinogen to fibrin and is the most powerful platelet activator known. Anticoagulants therefore target thrombin or Factor Xa: unfractionated heparin and enoxaparin potentiate antithrombin; fondaparinux is a selective indirect Factor Xa inhibitor; bivalirudin is a direct thrombin inhibitor.[8][9]

4. Dynamic obstruction and vasoconstriction — serotonin and thromboxane A2 from platelets cause local coronary vasoconstriction; superimposed epicardial spasm or microvascular dysfunction may even produce transient ST elevation. The obstruction in NSTE-ACS is therefore dynamic, waxing and waning — the substrate for crescendo and rest angina and for the dynamic ST-T changes on serial ECGs.[1]

5. Distal embolisation and the troponin leak — micro-fragments of the platelet-fibrin thrombus embolise downstream, plugging the microcirculation and producing patchy, subendocardial, non-transmural necrosis. Necrotic cardiomyocytes release cardiac troponin I and T — detectable by high-sensitivity assays at 1 to 3 hours, peaking around 18 to 24 hours, persisting 7 to 14 days. The troponin rise/fall is the biochemical signature that separates NSTEMI from unstable angina, and because the necrosis is patchy and subendocardial the ECG shows ST depression or T inversion rather than ST elevation, with no pathological Q waves.[1]

Meet the atypical presentations — the ones that bite

Typical NSTE-ACS pain shares the character of stable angina but breaks the stable rules — it is new, crescendo, or at rest:[1]

• Quality — central, retrosternal pressure, tightness, band-like heaviness or crushing ("an elephant on the chest"); rarely sharp or stabbing.
• Duration — typically 10 to 30 minutes; longer than stable angina, not the seconds of musculoskeletal pain nor the hours-to-days of muscular or oesophageal pain.
• Radiation — to the left arm, both arms, neck, jaw, shoulders, epigastrium, or back.
• Provocation and relief — the defining feature of the unstable pattern: occurs at rest, with progressively less exertion, or continues after exertion stops; not reliably relieved by sublingual GTN; may wake the patient from sleep.
• Associations — dyspnoea (the commonest anginal equivalent), diaphoresis, nausea and vomiting (especially inferior territory), fatigue, palpitations, a sense of doom.[1]

The three classical unstable-angina presentations (Braunwald III B is the textbook one):[1]

1. Rest angina — angina at rest, usually over 20 minutes (the commonest).
2. New-onset severe angina — new angina of at least Canadian Cardiovascular Society Class III within 2 months.
3. Crescendo angina — known angina that has become distinctly more frequent, longer, or lower in threshold within 2 months.[1]

The atypical triad the examiner is fishing for: elderly, diabetic, or female patients commonly present with dyspnoea, fatigue, epigastric discomfort, syncope, or delirium rather than chest pressure — and isolated dyspnoea is the single commonest anginal equivalent. A troponin is part of the work-up of any elderly patient with unexplained dyspnoea, syncope, or new confusion; missing a painless NSTE-ACS in a diabetic with "new heart failure" is a classic failure mode.[3]

Two more atypical groups the viva rewards: post-operative patients (pain masked by analgesia and surgical wounds; NSTE-ACS presents as hypotension, new atrial fibrillation, pulmonary oedema, or unexplained tachycardia) and cocaine-induced NSTE-ACS (young patient, sympathetic toxicity, mechanism a mixture of spasm, thrombosis, and demand ischaemia).[1]

The killers that mimic NSTE-ACS — exclude the dissection first

Several life-threatening mimics must be ruled out before you commit to dual antiplatelet and anticoagulant therapy, because those drugs can be catastrophic if the true diagnosis is one of them. The five immediately life-threatening causes of chest pain (the exam staple) are ACS, aortic dissection, pulmonary embolism, tension pneumothorax, and oesophageal rupture (Boerhaave) — all but pneumothorax can masquerade as NSTE-ACS.[1]

[1]

The single differential to exclude clinically before the first aspirin is aortic dissection: tearing, migrating pain to the back, a pulse or blood-pressure differential over 20 mmHg between limbs, a new aortic regurgitation murmur, a widened mediastinum on chest X-ray. Anticoagulating a dissection is potentially fatal, so the bundle waits until that possibility is addressed. Also name the two imaging mimics: Takotsubo (stress) cardiomyopathy (troponin rise with wall-motion abnormality beyond a single coronary territory, triggered by emotional or physical stress, no obstructive culprit) and myocarditis (troponin-positive with diffuse ST-T change and a viral prodrome, no culprit at angiography).[1]

The bedside round — hunt for the very-high-risk phenotype

Examination in suspected NSTE-ACS rarely provides a diagnostic sign; its job is to detect the very-high-risk phenotype and the complications. Run the focused round in this order:[1]

• Vital signs — heart rate, blood pressure, respiratory rate, oxygen saturation, temperature. Shock (hypotension, cold peripheries) and acute heart failure are very-high-risk features mandating immediate invasive strategy within 2 hours.
• Blood pressure in both arms — a differential over 20 mmHg raises dissection.
• Killip class — I no crackles or S3; II basilar crackles or S3; III pulmonary oedema; IV cardiogenic shock. Higher Killip drives GRACE and mortality.
• New murmur — a new pansystolic murmur with sudden collapse days after an ACS is a mechanical complication (papillary muscle rupture, ventricular septal rupture) — a surgical emergency.
• Signs of an alternative diagnosis — pericardial rub, unequal pulses (dissection), pleural rub or calf tenderness (PE), tender chest wall (musculoskeletal).[1]

Bedside tests during assessment: finger-prick glucose (diabetic ketoacidosis can mimic chest pain; hyperglycaemia worsens prognosis), haemoglobin (anaemia may be the Type 2 trigger and modifies bleeding risk), and a venous gas or lactate if shock is suspected.[1]

Risk stratification — the scores that set the timing

Risk stratification is the heart of NSTE-ACS — it alone sets the clock on angiography. Reproduce the named scores verbatim; examiners want the components and the bands.[1]

The TIMI risk score for NSTE-ACS — one point each, maximum 7:[2]

1. Age 65 years or older.
2. At least 3 risk factors for CAD (family history, hypertension, hypercholesterolaemia, diabetes, current smoker).
3. Known CAD (coronary stenosis 50 per cent or more).
4. Aspirin use in the past 7 days.
5. Severe angina (at least 2 anginal events in the past 24 hours).
6. ST-segment deviation of 0.5 mm or more on ECG.
7. Elevated cardiac markers (troponin or CK-MB).[1]

TIMI bands (14-day rate of all-cause mortality, new or recurrent MI, or severe recurrent ischaemia requiring urgent revascularisation): score 0 to 1 about 4.7 per cent (low); 2 about 8.3 per cent; 3 about 13.2 per cent; 4 about 19.9 per cent; 5 about 26.2 per cent; 6 to 7 about 40.9 per cent (high). A TIMI of 3 or more generally supports an invasive strategy.[1]

The GRACE score (Global Registry of Acute Coronary Events) — the ESC-preferred model for in-hospital and 6-month mortality, combining eight weighted variables:[1]

1. Age.
2. Heart rate at admission.
3. Systolic blood pressure at admission.
4. Creatinine (renal function).
5. Killip class at presentation.
6. Cardiac arrest at admission.
7. ST-segment deviation on the ECG.
8. Abnormal cardiac enzymes (troponin).[1]

Because the points are non-linear and tabulated, GRACE is computed with an app or calculator. Risk bands (in-hospital mortality): low (GRACE under 109, mortality about 1 per cent or less); intermediate (109 to 140, about 1 to 3 per cent); high (above 140, about 3 per cent and rising sharply). GRACE is the score the ESC uses to set the timing of invasive angiography.[1]

Two further scores balance the other questions: HEART (History, ECG, Age, Risk factors, Troponin; 0 to 2 points each, maximum 10) predicts 6-week major adverse cardiac events in the undifferentiated emergency-department chest-pain patient — 0 to 3 low risk (about 1.7 per cent MACE, consider discharge), 4 to 6 moderate, 7 to 10 high (about 50 per cent). CRUSADE predicts in-hospital major bleeding from baseline haematocrit, eGFR, heart rate, sex, congestive heart failure, prior vascular disease, diabetes, and systolic blood pressure — run it before intensifying antithrombotic therapy.[3]

The one-line score map: GRACE for death, TIMI and HEART for ischaemic risk, CRUSADE for bleeding — know which score answers which question.[1]

Adjunct investigations: chest X-ray (pulmonary oedema, widened mediastinum raising dissection, pneumothorax, pneumonia); transthoracic echocardiogram (regional wall-motion abnormality supporting ischaemia, ejection fraction, mechanical complications, aortic root); bloods (full blood count, urea and electrolytes, creatinine and eGFR, glucose, fasting lipids within 24 to 48 hours because LDL falls after 24 to 48 h, liver and thyroid function, coagulation, D-dimer if PE is in the differential, group and save); and coronary angiography, the definitive investigation and the gateway to PCI. CT coronary angiography rules out disease in low-risk patients once ACS is excluded — but not in the confirmed NSTE-ACS patient.[1]

The immediate bundle — delivered in parallel, not after the troponin

[1]

The immediate management of suspected NSTE-ACS is a standardised bundle delivered in parallel with the work-up; none of it waits for the troponin if the clinical and ECG picture is consistent. ABCDE first; continuous ECG monitoring; IV access; defibrillator at the bedside.[1]

[4]

Two warnings the bundle carries. First, routine oxygen in a normoxic patient is harmful — reserve it for SpO2 under 90 per cent (under 88 per cent in chronic CO2-retaining COPD). Second, morphine slows gastric emptying and blunts the peak of oral ticagrelor and clopidogrel — give the oral antiplatelet first, use morphine judiciously, and consider crushing ticagrelor.[1]

Aspirin deserves its own sentence. ISIS-2 randomised over 17,000 patients with suspected acute MI to intravenous streptokinase, oral aspirin, both, or neither: aspirin alone cut 5-week vascular mortality by 23 per cent — as much as streptokinase — and the combination halved mortality. It is the best-evidenced single treatment in acute MI and the foundation of every NSTE-ACS bundle.[4]

[1]

DAPT — name the drug, the dose, the trial

Dual antiplatelet therapy is the foundation: aspirin indefinitely plus a P2Y12 inhibitor, by default for 12 months after NSTE-ACS, agent chosen by efficacy, bleeding risk, cost, and access. The landmark trials are core exam material:[1]

[5]

Anticoagulation — fondaparinux for conservative, heparin family for invasive

Parenteral anticoagulation is started with the antiplatelets and runs until PCI is completed (or through the index admission in a conservatively managed patient). The four options:[1]

• Fondaparinux 2.5 mg subcutaneous once daily — preferred for a conservative strategy: in OASIS-5 it matched enoxaparin for ischaemic events with significantly less major bleeding and lower mortality at 30 days and 6 months. If the patient proceeds to PCI on fondaparinux, add a single bolus of UFH (fondaparinux alone risks catheter thrombosis).
• Enoxaparin 1 mg/kg subcutaneous twice daily (reduce to once daily if eGFR under 30 mL/min); a 0.5 mg/kg IV bolus is given at PCI.
• Unfractionated heparin 60 to 70 IU/kg IV bolus (max 4000 to 5000 IU) then 12 to 15 IU/kg/hour infusion titrated to APTT 1.5 to 2.5 times control — preferred when rapid reversibility is needed (renal failure, high bleeding risk, the catheter lab).
• Bivalirudin 0.75 mg/kg IV bolus then 1.75 mg/kg/hour — a direct thrombin inhibitor; in ACUITY and MATRIX it gave ischaemic protection comparable to heparin plus a GP-IIb/IIIa inhibitor with less bleeding, an option for an invasive strategy.[8][9][10]

GP-IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) are no longer used routinely upstream. The EARLY-ACS trial showed that routine early, upstream eptifibatide was not superior and bled more than provisional (bail-out) use during PCI — reserve them for thrombotic complications during PCI (large thrombus burden, slow or no reflow, bail-out).[14]

When to take the patient to the cath lab — the 2-24-72 rule

The pivotal, exam-decisive decision in NSTE-ACS is when to take the patient to the catheter laboratory. Unlike STEMI, the right answer is not "everyone, now" — it is a graded, risk-stratified escalation, reproduced verbatim from the ESC 2023 timing bands:[1]

[2]

The 2-24-72 number rule: very-high-risk features buy the cath lab within 2 hours; high-risk features buy it within 24 hours; intermediate-risk within 72 hours; low-risk patients get non-invasive testing, not a routine angiogram. Memorise the very-high-risk triggers by name — shock, life-threatening arrhythmia or arrest, mechanical complication, acute heart failure, recurrent dynamic ST-T change — because each one overrides the score.[1]

The evidence base for an invasive strategy in medium- to high-risk NSTE-ACS rests on three landmark trials and their meta-analyses: an early invasive approach reduces death, MI, and refractory ischaemia over the medium term, with benefit concentrated in high-risk, troponin-positive, ST-change-positive patients and durable at 5 years.[11][12][13]

Revascularisation — PCI (drug-eluting stent) for the culprit and, increasingly, complete revascularisation of significant non-culprit lesions in multivessel disease to cut recurrent events. CABG for left main stem disease, three-vessel disease (especially with LV dysfunction or diabetes), and complex anatomy (SYNTAX score). The heart team decides.[1]

Secondary prevention — the disease-modifying bundle

Every NSTE-ACS survivor leaves hospital on the same disease-modifying bundle, as examinable as the acute ladder:[1]

[15] [16] [17]

This bundle, plus lifestyle (Mediterranean diet, regular exercise, weight management, alcohol moderation), drives the long-term reduction in recurrent events. DAPT for a minimum of 12 months is the default unless bleeding risk is prohibitive; ticagrelor 60 mg twice daily plus low-dose aspirin prolongs DAPT beyond 12 months in patients with high ischaemic and low bleeding risk, while de-escalation (P2Y12 monotherapy after 1 to 3 months) is considered in high bleeding risk after PCI. Aspirin, the high-intensity statin, the beta-blocker, and the ACE inhibitor continue long-term.[1]

When NSTE-ACS kills the patient later — complications by the clock

Complications separate by timing, and the timing is the most examinable single fact about each. The clock matters more than the murmur.[1]

[1]

The three mechanical complications classically strike days 2 to 7, when necrosis has softened the myocardium to mush, and each carries a characteristic murmur — so a new pansystolic murmur days after ACS with sudden collapse is a red flag demanding urgent echocardiography and cardiothoracic surgical referral. Mortality climbs hourly.[1]

Bleeding is the complication of our own therapy and the major determinant of outcome — a major bleed doubles 30-day mortality. Prevent it by radial access (60 to 70 per cent reduction in access-site bleeding), renal dose-adjustment of enoxaparin and fondaparinux, avoiding upstream GP-IIb/IIIa inhibitors, and running the CRUSADE score prospectively. Protamine reverses UFH (and partially enoxaparin); fondaparinux is not reversed by protamine; for life-threatening bleeding on ticagrelor or prasugrel, give platelet transfusion and supportive care. Contrast-induced acute kidney injury is prevented by periprocedural isotonic saline hydration, minimised contrast, and holding nephrotoxins.[1]

Stent thrombosis — acute (under 24 hours), subacute (1 to 30 days), late (1 to 12 months), very late (over 12 months) — presents as recurrent ACS, often catastrophic. Adherence to DAPT is the single most important preventable cause.[1]

The recurring pitfalls every candidate must name:[1]

• Treating NSTE-ACS like STEMI — there is no immediate-reperfusion mandate; over-rapid intervention in low-risk patients adds bleeding without benefit.
• Missing the very-high-risk patient — failing to recognise shock or dynamic ST-T change as the trigger for immediate invasive within 2 hours.
• Giving aspirin before excluding aortic dissection — a fatal, irreversible error.
• Over-interpreting a single troponin in renal failure or chronic heart failure — use the rise/fall pattern, not an isolated value.
• Routine supplemental oxygen in the normoxic patient.
• Stopping DAPT early (for a non-cardiac procedure, say) without bridging — precipitates stent thrombosis.
• Forgetting atypical presentations in the elderly, diabetic, and post-operative patient.[1]

How NSTE-ACS patients come to harm — the preventable list

• Death from an unrecognised aortic dissection that was anticoagulated as atypical NSTE-ACS — the preventable death.[1]
• A posterior STEMI read as NSTEMI with ST depression, delaying reperfusion.[1]
• A very-high-risk NSTE-ACS (shock, dynamic ST-T change) filed as stable NSTEMI and given a 72-hour angiogram instead of a 2-hour one.[1]
• A Type 2 MI in sepsis loaded with DAPT and sent for angiography, with a bleeding complication and no ischaemic benefit.[1]
• A mechanical complication on day 4 misread as just heart failure when a new murmur was the clue.[1]
• Aspirin omitted for a possible gastritis chest pain, or for a soft, non-absolute contraindication.[4]
• DAPT stopped at three months because the patient felt well, with stent thrombosis the result.[1]

Prognosis and disposition — set by the score

In-hospital mortality of NSTE-ACS is around 3 to 5 per cent — lower than STEMI — but 1-year mortality equals or exceeds STEMI (around 10 to 15 per cent) because NSTE-ACS patients are older, sicker, and more often have multivessel and recurrent disease. The GRACE score is the validated predictor of in-hospital and 6-month mortality; TIMI predicts the composite ischaemic endpoint. Poor-outcome predictors include older age, diabetes, chronic kidney disease, heart failure or LV dysfunction, troponin elevation, dynamic ST changes, anaemia, and raised inflammatory markers.[1]

Disposition. Admit to a monitored coronary care unit or cardiac monitored bed with continuous ECG and a defibrillator at the bedside. Once stable and revascularised, step down to a ward, then home with the full secondary-prevention bundle — aspirin, P2Y12 inhibitor to complete 12 months, high-intensity statin, beta-blocker, ACE inhibitor — plus smoking cessation, cardiac rehabilitation, diabetes and hypertension control, diet and exercise, influenza and pneumococcal vaccination, and a clear follow-up plan within 2 to 4 weeks to titrate medicines, check DAPT adherence, and address residual ischaemia.[1]

Special populations — the subtypes that bite

[1]

Elderly (75 or over). Atypical presentations (dyspnoea, delirium, syncope) are the norm; bleeding risk is higher, so dose-adjust antithrombotics (prasugrel 5 mg if used; caution with enoxaparin), prefer radial access, and keep a low threshold to admit and troponin-test. Prasugrel is contraindicated at 75 or over and at under 60 kg or prior stroke or TIA.[1]

Diabetes mellitus. More extensive disease, worse prognosis, often painless; benefit greatly from an invasive strategy and complete revascularisation. Ticagrelor is preferred over clopidogrel when affordable (PLATO diabetic subgroup). In-hospital glycaemic control avoids both marked hyper- and hypoglycaemia; continue metformin peri-procedurally with renal monitoring, and SGLT2 inhibitors and GLP-1 receptor agonists for long-term cardiovascular protection.[1]

Chronic kidney disease (eGFR under 60). High-risk by definition (intermediate-risk invasive strategy within 72 hours); troponin is chronically elevated, so the delta (rise/fall) is decisive. Dose-adjust enoxaparin, fondaparinux (contraindicated if CrCl under 20 mL/min), and bivalirudin; favour UFH at very low eGFR for its reversibility; use contrast-sparing angiography with periprocedural hydration.[1]

Patients already on an oral anticoagulant (atrial fibrillation, mechanical valve, VTE) — the highest bleeding-risk subgroup. Aspirin plus clopidogrel (not ticagrelor or prasugrel) plus the OAC; minimise triple therapy to the peri-PCI window (up to 1 week), then dual therapy (OAC plus clopidogrel) to 6 to 12 months, then OAC monotherapy. Prefer radial access, a DOAC over a VKA when eligible, and add gastroprotection with a PPI.[1]

Cocaine-induced NSTE-ACS. Mechanism is vasospasm with or without plaque rupture plus a hyperadrenergic state. Benzodiazepines first (relieve sympathetic drive and spasm), then aspirin, nitrates, and a calcium-channel blocker; avoid beta-blockers acutely (unopposed alpha-mediated vasoconstriction — though modern evidence is less absolute, the exam answer remains beta-blocker caution). Anticoagulate and risk-stratify as usual; still consider angiography if STEMI criteria are met.[1]

Pregnancy. NSTE-ACS is rare (incidence rising with advanced maternal age and pre-eclampsia); spontaneous coronary artery dissection is an important cause in the peripartum period and is managed conservatively if stable. Manage with aspirin, beta-blocker, and unfractionated heparin (does not cross the placenta); avoid statins (teratogenic); prefer bare-metal stenting if PCI is needed (shorter DAPT) and avoid GP-IIb/IIIa unless essential. Multidisciplinary with obstetrics and cardiology.[1]

NSTE-ACS with cardiogenic shock. Immediate invasive strategy within 2 hours; consider short-term mechanical circulatory support (intra-aortic balloon pump, Impella, VA-ECMO) as a bridge; revascularise the culprit and significant lesions. Mortality is high.[1]

The trials that changed NSTE-ACS practice

The landmark trials an examiner expects you to cite, and what each changed:[1]

[4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]

Guidelines and regional deltas. The ESC 2023 ACS guideline is the current European standard for the risk-stratified invasive timing above, unifying STEMI and NSTE-ACS into one syndrome document. The 2014 AHA/ACC NSTE-ACS guideline (Amsterdam) is the North American counterpart — broadly concordant, with a very early invasive strategy within 24 hours for high-risk patients, high-intensity statin, and DAPT. The 2021 AHA/ACC Chest Pain guideline (Gulati) reinforces troponin as the preferred biomarker (CK-MB and myoglobin should not be used routinely) and a low threshold to test in the undifferentiated chest-pain patient.[2][3]

[1]

Controversies to name calmly: the optimal timing of the invasive strategy in high-risk NSTE-ACS has compressed from within 24 hours to within 12 hours (VERDICT) with non-inferior outcomes and a bleeding signal favouring earlier intervention; complete versus culprit-only revascularisation has shifted toward complete in multivessel disease; and P2Y12 monotherapy (dropping aspirin after 1 to 3 months) is expanding in high bleeding-risk patients after PCI.[1]

The mantra

The mantra: ECG in ten minutes, aspirin three hundred milligrams, troponin on a 0/1-hour clock — then let the GRACE score, not your instinct, set the cath-lab timer.[1][4]

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)

The 66-year-old diabetic with rest chest pain, 1 mm of horizontal ST depression in V4 to V6, and a troponin twice the 99th centile. GRACE 138, no ongoing pain, haemodynamically stable. When do you take him to the cath lab? Model: This is intermediate-risk NSTE-ACS (GRACE 109 to 140, troponin rise, ST depression but now pain-free and stable). The 2-24-72 rule puts him on the 72-hour invasive pathway — angiography during this admission but not emergent. He gets the immediate bundle (aspirin 300 mg chewed, ticagrelor 180 mg, a parenteral anticoagulant, atorvastatin 80 mg within 24 hours), continuous monitoring, and cardiology review. If he develops recurrent dynamic ST-T change, shock, or a mechanical complication, he is reclassified to very high risk and moved to the 2-hour pathway.[1]

Stem 2 — the septic patient with a troponin bump (answer)

A 74-year-old on the ward with sepsis, heart rate 122, known coronary disease, has a troponin of 180 ng/L and a normal ECG. The registrar wants to load DAPT and call the cath lab. What is the right call? Model: This is Type 2 MI (supply-demand mismatch from tachycardia and hypotension on fixed coronary disease), or acute myocardial injury without ischaemic evidence — neither is the plaque-rupture pathway. Treat the precipitant: source control, fluids, oxygen, and rate control. Loading DAPT and rushing to angiography is the recurring trainee error that exposes the patient to bleeding without addressing the cause. Reserve the Type 1 NSTE-ACS pathway for ischaemic symptoms, new ECG changes, or a clear rise/fall troponin pattern in the right context.[1]

Stem 3 — the ECG that is not what it looks like (answer)

A 59-year-old smoker presents with ongoing chest pain; the ECG shows ST depression in V1 to V3 with tall R waves and upright T waves. The junior labels it low-risk NSTEMI. What is the trap, and what do you do? Model: This is a true posterior STEMI-equivalent, not low-risk NSTE-ACS. ST depression with tall R waves in V1 to V3 is the mirror image of posterior ST elevation. Record posterior leads V7 to V9 for confirmation, then activate reperfusion as for STEMI (primary PCI within 120 minutes or fibrinolysis). Filing this patient as low-risk NSTE-ACS on the standard 12-lead alone delays reperfusion — this is exactly why you reach for V7 to V9 whenever V1 to V3 looks odd.[1]

References

1. [1]Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes Eur Heart J, 2023.PMID 37622654
2. [2]Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol, 2014.PMID 25260718
3. [3]Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol, 2021.PMID 34756653
4. [4]ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet, 1988.PMID 2899772
5. [5]Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med, 2001.PMID 11519503
6. [6]Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med, 2009.PMID 19717846
7. [7]Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med, 2007.PMID 17982182
8. [8]Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med, 2006.PMID 16537663
9. [9]Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes N Engl J Med, 2006.PMID 17124018
10. [10]Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes N Engl J Med, 2015.PMID 26324049
11. [11]FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators Lancet, 1999.PMID 10475181
12. [12]Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina Lancet, 2002.PMID 12241831
13. [13]de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes N Engl J Med, 2005.PMID 16162880
14. [14]Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med, 2009.PMID 19332455
15. [15]Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med, 2004.PMID 15007110
16. [16]Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med, 2015.PMID 26039521
17. [17]Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med, 2000.PMID 10639539